



2021 Results of Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') advises that the resolutions contained in the Notice of Meeting dated 18 October 2021 and considered at today's Annual General Meeting of Shareholders were all passed by the required majority following a poll conducted at the meeting. The proxies received in respect of each resolution are set in the attached proxy summary.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

For further information, please contact:

Kevin Hart

Company Secretary

+61 8 9316 9100

info@pyctx.com

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth)

Resolution Details

Resolution	Type	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result Carried/ Not Carried
		For	Against	Discretionary	Abstain	For	Against	Abstain	
1. Remuneration Report	Ordinary	555,689,853 99.40%	246,576 0.04%	3,119,569 0.56%	1,387,388	589,186,141 99.96%	246,576 0.04%	1,387,388	Carried
2. Re-Election of Mr Alan Tribe	Ordinary	799,708,329 99.60%	16,576 0.00%	3,203,877 0.40%	350,000	833,288,925 100.00%	16,576 0.00%	39,950,000	Carried
3. Re-Election of Dr Michael Rosenblatt	Ordinary	799,708,329 99.60%	16,576 0.00%	3,203,877 0.40%	350,000	872,888,925 100.00%	16,576 0.00%	350,000	Carried
4. Re-Election of Mr Jason Haddock	Ordinary	799,708,329 99.60%	16,576 0.00%	3,203,877 0.40%	350,000	872,888,925 100.00%	16,576 0.00%	350,000	Carried
5. Approval of change of Auditor	Ordinary	799,506,329 99.57%	216,576 0.03%	3,203,877 0.40%	352,000	872,686,925 99.98%	217,576 0.02%	352,000	Carried

The Company notes that Mr Sahm Nasseri did not seek re-election at today's Annual General Meeting and therefore is no longer a Director.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California. For more information, visit pyctx.com, or follow us on [LinkedIn](https://www.linkedin.com/company/pyc-therapeutics) and [Twitter](https://twitter.com/pyc_therapeutics).

CONTACTS:

INVESTORS

info@pyctx.com

MEDIA

info@pyctx.com